640 related articles for article (PubMed ID: 30026324)
1. Targeting CCR8 Induces Protective Antitumor Immunity and Enhances Vaccine-Induced Responses in Colon Cancer.
Villarreal DO; L'Huillier A; Armington S; Mottershead C; Filippova EV; Coder BD; Petit RG; Princiotta MF
Cancer Res; 2018 Sep; 78(18):5340-5348. PubMed ID: 30026324
[TBL] [Abstract][Full Text] [Related]
2. Fc-Optimized Anti-CCR8 Antibody Depletes Regulatory T Cells in Human Tumor Models.
Campbell JR; McDonald BR; Mesko PB; Siemers NO; Singh PB; Selby M; Sproul TW; Korman AJ; Vlach LM; Houser J; Sambanthamoorthy S; Lu K; Hatcher SV; Lohre J; Jain R; Lan RY
Cancer Res; 2021 Jun; 81(11):2983-2994. PubMed ID: 33757978
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic depletion of CCR8
Van Damme H; Dombrecht B; Kiss M; Roose H; Allen E; Van Overmeire E; Kancheva D; Martens L; Murgaski A; Bardet PMR; Blancke G; Jans M; Bolli E; Martins MS; Elkrim Y; Dooley J; Boon L; Schwarze JK; Tacke F; Movahedi K; Vandamme N; Neyns B; Ocak S; Scheyltjens I; Vereecke L; Nana FA; Merchiers P; Laoui D; Van Ginderachter JA
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589525
[TBL] [Abstract][Full Text] [Related]
4. CCR8 blockade primes anti-tumor immunity through intratumoral regulatory T cells destabilization in muscle-invasive bladder cancer.
Wang T; Zhou Q; Zeng H; Zhang H; Liu Z; Shao J; Wang Z; Xiong Y; Wang J; Bai Q; Xia Y; Wang Y; Liu L; Zhu Y; Xu L; Dai B; Guo J; Chang Y; Wang X; Xu J
Cancer Immunol Immunother; 2020 Sep; 69(9):1855-1867. PubMed ID: 32367308
[TBL] [Abstract][Full Text] [Related]
5. CCR8-targeted specific depletion of clonally expanded Treg cells in tumor tissues evokes potent tumor immunity with long-lasting memory.
Kidani Y; Nogami W; Yasumizu Y; Kawashima A; Tanaka A; Sonoda Y; Tona Y; Nashiki K; Matsumoto R; Hagiwara M; Osaki M; Dohi K; Kanazawa T; Ueyama A; Yoshikawa M; Yoshida T; Matsumoto M; Hojo K; Shinonome S; Yoshida H; Hirata M; Haruna M; Nakamura Y; Motooka D; Okuzaki D; Sugiyama Y; Kinoshita M; Okuno T; Kato T; Hatano K; Uemura M; Imamura R; Yokoi K; Tanemura A; Shintani Y; Kimura T; Nonomura N; Wada H; Mori M; Doki Y; Ohkura N; Sakaguchi S
Proc Natl Acad Sci U S A; 2022 Feb; 119(7):. PubMed ID: 35140181
[TBL] [Abstract][Full Text] [Related]
6. Therapy of Established Tumors with Rationally Designed Multiple Agents Targeting Diverse Immune-Tumor Interactions: Engage, Expand, Enable.
Fabian KP; Malamas AS; Padget MR; Solocinski K; Wolfson B; Fujii R; Abdul Sater H; Schlom J; Hodge JW
Cancer Immunol Res; 2021 Feb; 9(2):239-252. PubMed ID: 33355290
[TBL] [Abstract][Full Text] [Related]
7. In situ analysis of CCR8
Hayashi Y; Ueyama A; Funaki S; Jinushi K; Higuchi N; Morihara H; Hirata M; Nagira Y; Saito T; Kawashima A; Iwahori K; Shintani Y; Wada H
BMC Cancer; 2024 May; 24(1):627. PubMed ID: 38783281
[TBL] [Abstract][Full Text] [Related]
8. Suppression of Tregs by anti-glucocorticoid induced TNF receptor antibody enhances the antitumor immunity of interferon-α gene therapy for pancreatic cancer.
Aida K; Miyakawa R; Suzuki K; Narumi K; Udagawa T; Yamamoto Y; Chikaraishi T; Yoshida T; Aoki K
Cancer Sci; 2014 Feb; 105(2):159-67. PubMed ID: 24289533
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy Targeting CCR8+ Regulatory T Cells Induces Antitumor Effects via Dramatic Changes to the Intratumor CD8+ T Cell Profile.
Ueyama A; Nogami W; Nashiki K; Haruna M; Miwa H; Hagiwara M; Nagira M; Wada H; Nagira Y
J Immunol; 2023 Aug; 211(4):673-682. PubMed ID: 37350632
[TBL] [Abstract][Full Text] [Related]
10. Ontak reduces the immunosuppressive tumor environment and enhances successful therapeutic vaccination in HER-2/neu-tolerant mice.
Gritzapis AD; Voutsas IF; Baxevanis CN
Cancer Immunol Immunother; 2012 Mar; 61(3):397-407. PubMed ID: 21928125
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Nr4a Receptors Enhances Antitumor Immunity by Breaking Treg-Mediated Immune Tolerance.
Hibino S; Chikuma S; Kondo T; Ito M; Nakatsukasa H; Omata-Mise S; Yoshimura A
Cancer Res; 2018 Jun; 78(11):3027-3040. PubMed ID: 29559474
[TBL] [Abstract][Full Text] [Related]
12. The impact of CCR8+ regulatory T cells on cytotoxic T cell function in human lung cancer.
Haruna M; Ueyama A; Yamamoto Y; Hirata M; Goto K; Yoshida H; Higuchi N; Yoshida T; Kidani Y; Nakamura Y; Nagira M; Kawashima A; Iwahori K; Shintani Y; Ohkura N; Wada H
Sci Rep; 2022 Mar; 12(1):5377. PubMed ID: 35354899
[TBL] [Abstract][Full Text] [Related]
13. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
14. Agonist anti-GITR antibody significantly enhances the therapeutic efficacy of Listeria monocytogenes-based immunotherapy.
Shrimali R; Ahmad S; Berrong Z; Okoev G; Matevosyan A; Razavi GSE; Petit R; Gupta S; Mkrtichyan M; Khleif SN
J Immunother Cancer; 2017 Aug; 5(1):64. PubMed ID: 28807056
[TBL] [Abstract][Full Text] [Related]
15. Dual Roles for Regulatory T-cell Depletion and Costimulatory Signaling in Agonistic GITR Targeting for Tumor Immunotherapy.
Mahne AE; Mauze S; Joyce-Shaikh B; Xia J; Bowman EP; Beebe AM; Cua DJ; Jain R
Cancer Res; 2017 Mar; 77(5):1108-1118. PubMed ID: 28122327
[TBL] [Abstract][Full Text] [Related]
16. Alteration of the Tumor Stroma Using a Consensus DNA Vaccine Targeting Fibroblast Activation Protein (FAP) Synergizes with Antitumor Vaccine Therapy in Mice.
Duperret EK; Trautz A; Ammons D; Perales-Puchalt A; Wise MC; Yan J; Reed C; Weiner DB
Clin Cancer Res; 2018 Mar; 24(5):1190-1201. PubMed ID: 29269377
[No Abstract] [Full Text] [Related]
17. A Neuropilin-1 Antagonist Exerts Antitumor Immunity by Inhibiting the Suppressive Function of Intratumoral Regulatory T Cells.
Jung K; Kim JA; Kim YJ; Lee HW; Kim CH; Haam S; Kim YS
Cancer Immunol Res; 2020 Jan; 8(1):46-56. PubMed ID: 31554638
[TBL] [Abstract][Full Text] [Related]
18. CCR8 marks highly suppressive Treg cells within tumours but is dispensable for their accumulation and suppressive function.
Whiteside SK; Grant FM; Gyori DS; Conti AG; Imianowski CJ; Kuo P; Nasrallah R; Sadiyah F; Lira SA; Tacke F; Eil RL; Burton OT; Dooley J; Liston A; Okkenhaug K; Yang J; Roychoudhuri R
Immunology; 2021 Aug; 163(4):512-520. PubMed ID: 33838058
[TBL] [Abstract][Full Text] [Related]
19. Endogenous IL-33 exerts CD8
Xia Y; Ohno T; Nishii N; Bhingare A; Tachinami H; Kashima Y; Nagai S; Saito H; Nakae S; Azuma M
Biochem Biophys Res Commun; 2019 Oct; 518(2):331-336. PubMed ID: 31421832
[TBL] [Abstract][Full Text] [Related]
20. Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody.
Weaver JD; Stack EC; Buggé JA; Hu C; McGrath L; Mueller A; Wong M; Klebanov B; Rahman T; Kaufman R; Fregeau C; Spaulding V; Priess M; Legendre K; Jaffe S; Upadhyay D; Singh A; Xu CA; Krukenberg K; Zhang Y; Ezzyat Y; Saddier Axe D; Kuhne MR; Meehl MA; Shaffer DR; Weist BM; Wiederschain D; Depis F; Gostissa M
Oncoimmunology; 2022; 11(1):2141007. PubMed ID: 36352891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
